S-8 1 d319846ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on March 1, 2022

Registration No. 333-                    

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

BIOATLA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   85-1922320

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

BioAtla, Inc.

11085 Torreyana Road

San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

2020 Equity Incentive Plan

Employee Stock Purchase Plan

(Full title of the plans)

Jay M. Short, Ph.D.

Co-Founder, Chief Executive Officer and Chairman

BioAtla, Inc.

11085 Torreyana Road

San Diego, California 92121

(858) 558-0708

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

David Schulman, Esq.

Niki Fang, Esq.

Orrick, Herrington & Sutcliffe LLP

405 Howard Street

San Francisco, CA 94105

(415) 773-5700

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


REGISTRATION OF ADDITIONAL SHARES

PURSUANT TO GENERAL INSTRUCTION E

Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 1,431,969 additional shares of common stock under the 2020 Plan and 395,155 additional shares of common stock under the ESPP pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on December 18, 2020 (Registration No. 333-251520).

Item 8. Exhibits.

The following exhibits are filed herewith:

 

          Incorporated by Reference       

Exhibit

Number

   Exhibit Description    Form      File No.      Exhibit      Filing Date      Filed
Herewith
    5.1    Opinion of Orrick, Herrington & Sutcliffe LLP                X
  23.1    Consent of Orrick, Herrington & Sutcliffe LLP (included in Exhibit 5.1)                X
  23.2    Consent of Independent Registered Public Accounting Firm                X
  24.1    Power of Attorney (included on the signature page of this Registration Statement)                X
  99.1    2020 Equity Incentive Plan      S-1        333-250093        10.01        12/9/20     
  99.2    Amendment No. 1 to 2020 Equity Incentive Plan      S-8        333-251520        99.2        12/18/20     
  99.3    Amendment No. 2 to 2020 Equity Incentive Plan      10-K        001-39787        10.26        2/28/22     
  99.4    Employee Stock Purchase Plan      S-1        333-250093        10.01        12/9/20     
  99.5    Amendment No. 1 to Employee Stock Purchase Plan      10-K        001-39787        10.27        2/28/22     
107    Filing Fee Table                X


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 28, 2022.

 

BIOATLA, INC.

/s/ Jay M. Short, Ph.D.

Jay M. Short, Ph.D.
Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jay M. Short, Ph.D. and Richard A. Waldron, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

 

SIGNATURE    TITLE   DATE

/s/    Jay M. Short, Ph.D.        

   Chief Executive Officer and Director   February 28, 2022
Jay M. Short, Ph.D.    (Principal Executive Officer)  

/s/    Richard A. Waldron        

   Chief Financial Officer   February 28, 2022
Richard A. Waldron    (Principal Financial and Accounting Officer)  

/s/    Scott Smith        

   President and Director   February 28, 2022
Scott Smith     

/s/    Edward Williams        

   Director   February 28, 2022
Edward Williams     

/s/    Guy Levy        

   Director   February 28, 2022
Guy Levy     

/s/    Lawrence Steinman        

   Director   February 28, 2022
Lawrence Steinman     

/s/    Sylvia McBrinn        

   Director   February 28, 2022
Sylvia McBrinn     

/s/    Mary Ann Gray, Ph.D.        

   Director   February 28, 2022
Mary Ann Gray, Ph.D.     

/s/    Susan Moran, M.D.        

   Director   February 28, 2022
Susan Moran, M.D.